TY - JOUR
T1 - Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis
AU - Raut, Chandrajit P.
AU - Izzo, Francesco
AU - Marra, Paolo
AU - Ellis, Lee M.
AU - Vauthey, Jean Nicolas
AU - Cremona, Francesco
AU - Vallone, Paolo
AU - Mastro, Angelo
AU - Fornage, Bruno D.
AU - Curley, Steven A.
PY - 2005/8
Y1 - 2005/8
N2 - Background: Radiofrequency ablation (RFA) offers an alternative treatment in some unresectable hepatocellular carcinoma (HCC) patients with disease confined to the liver. We prospectively evaluated survival rates in patients with early-stage, unresectable HCC treated with RFA. Methods: All patients with HCC treated with RFA between September 1, 1997, and July 31, 2002, were prospectively evaluated. Patients were treated with RFA by using a percutaneous or open intraoperative approach with ultrasound guidance and were evaluated at regular intervals to determine disease recurrence and survival. Results: A total of 194 patients (153 men [79%] and 41 women [21%]) with a median age of 66 years (range, 39-86 years) underwent RFA of 289 sonographically detectable HCC tumors. All patients were followed up for at least 12 months (median follow-up, 34.8 months). Percutaneous and open intraoperative RFA was performed in 140 (72%) and 54 (28%) patients, respectively. The median diameter of tumors treated with RFA was 3.3 cm. Disease recurred in 103 (53%) of 194 patients, including 69 (49%) of 140 patients treated percutaneously and 34 (63%) of 54 treated with open RFA (not significant). Local recurrence developed in nine patients (4.6%). Most recurrence was intrahepatic. The overall complication rate was 12%. Overall survival rates at 1, 3, and 5 years for all 194 patients were 84.5%, 68.1%, and 55.4%, respectively. Conclusions: Treatment with RFA can produce significant long-term survival rates for cirrhotic patients with early-stage, unresectable HCC. RFA can be performed in these patients with relatively low complication rates. Confirmation of these results in randomized trials should be considered.
AB - Background: Radiofrequency ablation (RFA) offers an alternative treatment in some unresectable hepatocellular carcinoma (HCC) patients with disease confined to the liver. We prospectively evaluated survival rates in patients with early-stage, unresectable HCC treated with RFA. Methods: All patients with HCC treated with RFA between September 1, 1997, and July 31, 2002, were prospectively evaluated. Patients were treated with RFA by using a percutaneous or open intraoperative approach with ultrasound guidance and were evaluated at regular intervals to determine disease recurrence and survival. Results: A total of 194 patients (153 men [79%] and 41 women [21%]) with a median age of 66 years (range, 39-86 years) underwent RFA of 289 sonographically detectable HCC tumors. All patients were followed up for at least 12 months (median follow-up, 34.8 months). Percutaneous and open intraoperative RFA was performed in 140 (72%) and 54 (28%) patients, respectively. The median diameter of tumors treated with RFA was 3.3 cm. Disease recurred in 103 (53%) of 194 patients, including 69 (49%) of 140 patients treated percutaneously and 34 (63%) of 54 treated with open RFA (not significant). Local recurrence developed in nine patients (4.6%). Most recurrence was intrahepatic. The overall complication rate was 12%. Overall survival rates at 1, 3, and 5 years for all 194 patients were 84.5%, 68.1%, and 55.4%, respectively. Conclusions: Treatment with RFA can produce significant long-term survival rates for cirrhotic patients with early-stage, unresectable HCC. RFA can be performed in these patients with relatively low complication rates. Confirmation of these results in randomized trials should be considered.
KW - Cirrhosis
KW - Hepatocellular cancer
KW - Radiofrequency ablation
KW - Survival
KW - Unresectable
UR - http://www.scopus.com/inward/record.url?scp=23744497031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23744497031&partnerID=8YFLogxK
U2 - 10.1245/ASO.2005.06.011
DO - 10.1245/ASO.2005.06.011
M3 - Article
C2 - 15965731
AN - SCOPUS:23744497031
SN - 1068-9265
VL - 12
SP - 616
EP - 628
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 8
ER -